Table 3.
Individual voriconazole exposure parameters in young adolescents receiving 300 mg orally q12ha
| Subject (age [yr], sex)b | Wt (kg) | CYP2C19 type | IV steady state |
Oral steady state |
||
|---|---|---|---|---|---|---|
| AUC0–12 (μg·h/ml) | Cmax (μg/ml) | AUC0–12 (μg·h/ml) | Cmax (μg/ml) | |||
| 23 (12, F) | 30.4 | HEM | 40.1 | 9.82 | NA | NA |
| 26 (12, M)c | 39.0 | UM | 2.47 | 0.53 | 4.63 | 1.91 |
| 9 (12, F)d | 39.8 | EM | 6.27 | 2.26 | 1.17 | 0.18 |
| 25 (13, M) | 43.0 | UM | 8.29 | 2.44 | 14.6 | 2.84 |
| 21 (13, M) | 50.8 | EM | 16.3 | 2.95 | 14.8 | 1.96 |
| 24 (13, M) | 52.1 | NA | 49.9 | 4.87 | 15.5 | 2.09 |
| 12 (13, F) | 53.4 | HEM | 16.7 | 2.61 | 12.1 | 1.63 |
| 6 (12, M) | 56.8 | HEM | 37.2 | 4.69 | 26.5 | 3.59 |
| 4 (14, M) | 58.7 | HEM | 8.14 | 2.06 | 5.59 | 0.81 |
| 1 (14, M)e | 60.0 | EM | 10.4 | 2.5 | 11.9 | 1.54 |
| 7 (14, M) | 65.5 | HEM | 17 | 3.24 | 15.8 | 2.18 |
a
The subset with AUC0-12 of <16 μg·h/ml.
b
EM, homozygous extensive metabolizer; F, female; HEM, heterozygous extensive metabolizer; M, male; NA, not available; UM, ultrarapid extensive metabolizer.
c
This subject inadvertently received phenytoin 2 days prior to the first dose until day 5 of IV treatment.
d
This subject received 150 mg orally q12h (a reduced dose for subjects weighing less than 40 kg).
e
This subject missed the morning doses on the fourth day and sixth day of oral voriconazole.